GE HealthCare and Mayo Clinic Launch Theranostics Trial to Personalize Cancer Care

GE HealthCare and Mayo Clinic have launched the MI-BET trial, aiming to combine imaging and biomarker insights to tailor theranostics for cancer patients. No results yet—the announcement marks the start of this partnership-driven effort.

• The MI-BET trial will integrate advanced imaging with biomarker data to develop personalized theranostic strategies.
• This is a collaborative initiative between GE HealthCare (industry) and Mayo Clinic (academic center).
• The trial is in its early stages; no clinical outcomes or endpoints have been reported.

RadPigeon summaries are original and for information only. They are not clinical advice.